Authors:
TAMURA RN
BEASLEY CM
DELLVA MA
GLAZER WM
MORGENSTERN H
TOLLEFSON GD
Citation: Rn. Tamura et al., WHAT IS THE DIFFERENTIAL RISK OF TARDIVE-DYSKINESIA WITH THE NOVEL ANTIPSYCHOTIC OLANZAPINE, Schizophrenia research, 29(1-2), 1998, pp. 176-176
Authors:
SERNYAK MJ
GLAZER WM
HENINGER GR
CHARNEY DS
WOODS SW
PETRAKIS IL
KRYSTAL JH
PRICE LH
Citation: Mj. Sernyak et al., NALTREXONE AUGMENTATION OF NEUROLEPTICS IN SCHIZOPHRENIA, Journal of clinical psychopharmacology, 18(3), 1998, pp. 248-251
Citation: Wm. Glazer et Ra. Dickson, CLOZAPINE REDUCES VIOLENCE AND PERSISTENT AGGRESSION IN SCHIZOPHRENIA, The Journal of clinical psychiatry, 59, 1998, pp. 8-14
Citation: Wm. Glazer, OLANZAPINE AND THE NEW-GENERATION OF ANTIPSYCHOTIC AGENTS - PATTERNS OF USE, The Journal of clinical psychiatry, 58, 1997, pp. 18-21
Citation: Wm. Glazer et Bm. Johnstone, PHARMACOECONOMIC EVALUATION OF ANTIPSYCHOTIC THERAPY FOR SCHIZOPHRENIA, The Journal of clinical psychiatry, 58, 1997, pp. 50-54
Citation: Wm. Glazer, THE IMPACT OF MANAGED CARE SYSTEMS ON RELAPSE PREVENTION AND QUALITY-OF-LIFE FOR PATIENTS WITH SCHIZOPHRENIA, European neuropsychopharmacology, 6, 1996, pp. 35-39
Citation: Wm. Glazer et L. Ereshefsky, A PHARMACOECONOMIC MODEL OF OUTPATIENT ANTIPSYCHOTIC THERAPY IN REVOLVING-DOOR SCHIZOPHRENIC-PATIENTS, The Journal of clinical psychiatry, 57(8), 1996, pp. 337-345
Citation: Wm. Glazer et Gv. Gray, PSYCHOMETRIC PROPERTIES OF A DECISION-SUPPORT TOOL FOR THE ERA OF MANAGED CARE, Journal of mental health administration, 23(2), 1996, pp. 226-233
Citation: Jd. Slay et Wm. Glazer, CARVING IN, AND KEEPING IN, MENTAL-HEALTH-CARE IN THE MANAGED CARE SETTING, Psychiatric services, 46(11), 1995, pp. 1119
Citation: Wm. Glazer, THE PREFERRED PROVIDERS HANDBOOK - BUILDING A SUCCESSFUL PRIVATE THERAPY PRACTICE IN THE MARKETPLACE - POYNTER,WL, The American journal of psychiatry, 152(5), 1995, pp. 801-802
Citation: Wm. Glazer, MANAGING MANAGED CARE - A MENTAL-HEALTH PRACTITIONERS SURVIVAL GUIDE - GOODMAN,M, BROWN,J, DEITZ,P, The American journal of psychiatry, 152(1), 1995, pp. 146-146
Citation: Wm. Glazer et Jm. Kane, THE UNDERUTILIZATION OF DEPOT NEUROLEPTIC THERAPY - REPLY, The Journal of clinical psychiatry, 55(1), 1994, pp. 39-39
Citation: Wm. Glazer et H. Morgenstern, THE IMPACT OF UTILIZATION MANAGEMENT ON HOSPITAL LENGTH OF STAY AND ILLNESS, Administration and policy in mental health, 21(1), 1993, pp. 41-49
Citation: Mjr. England et Wm. Glazer, PSYCHOTIC RELAPSE - A MULTISYSTEMS PERSPECTIVE - DISCUSSANT SECTION, The Journal of clinical psychiatry, 54, 1993, pp. 35-36